PRME vs VRTS
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
PRME · Prime Medicine$4.65 ▲ 4.49%
VRTS · Virtus Investment$127.35 ▲ 1.99%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- PRME +31.9%
- VRTS -17.8%
Head to head
| Metric | PRME | VRTS |
|---|---|---|
| Price | $4.65 | $127.35 |
| Change today | ▲ 4.49% | ▲ 1.99% |
| Market cap | $843.40M | $843.40M |
| Return, 3 months | +47.6% | -23.2% |
| Return, year to date | +34.0% | -18.3% |
| Return, 1 year | +22.0% | -18.3% |
| P/E (TTM) | – | 7.3 |
| P/B | 21.2 | 0.9 |
| P/E percentile vs own 5y | 29th | 3rd |
| Dividend yield | – | 7.42% |
| Revenue growth (YoY, latest qtr) | +3.5% | -4.6% |
| Net profit growth (YoY) | +19.9% | +4.4% |
| Gross margin | – | 51.0% |
| Operating margin | -4,824.9% | 16.0% |
| Net margin | -4,613.1% | 14.6% |
| Return on equity | -18.2% | 13.0% |
| Analyst target vs. price | +64.9% | +1.9% |
| Analyst buy share | 88% | 25% |
| RSI (14) | 57 | 52 |
| 30-day volatility | 136.0% | 38.4% |
| Max drawdown, 1 year | -47.6% | -31.5% |
| Trend read | Strong uptrend | Leaning bullish |
| Analyst consensus | Buy | Hold |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- PRME is the largest of the group by market value.
- PRME has returned the most over the past year.
- PRME is growing revenue fastest.
- VRTS keeps the most profit per dollar of sales.
- VRTS has been the calmest stock over the last 30 days.